The Petri Dish: CRISPR halts cancer drug work; Apellis investors buoyed by FDA label

CRISPR Therapeutics has cut two cancer drug programs, while Apellis investors are breathing sigh of relief after a new FDA label. Plus other life science news you may have missed.

Previous Buffalo hospitals repurpose space as services migrate off campus
Next Owner of 36-story Denver office tower has defaulted on loan